Clinical Study on Marine Combined with Lamivudine and Thymosin a1 in the Treatment of Chronic Hepatitis B

Objective To evaluate the clinical efficacy of combination therapy of marine,lamivudine and thymosin a1 in chronic hepatitis B.Methods 118 chronic hepatitis B patients were enrolled and randomized into the therapy group and the control group.59 cases in the therapy group received marine,lamivudine and thymosin a1 for 13 weeks,then lamivudine and thymosin al for 13 weeks.At last lamivudine for 26 weeks;49 cases in the control group received lamivudine for 52 weeks.During the treatment blood routine examination of ALT,HBeAg,anti HBe,HBV DNA and HA were termly checked and measured.Results All 118 patients completed the study.The rates for ALT and HA to recover to normal and the rates for HBeAg/anti-HBe and HBV DNA to change to be negative in combination group were superior to those in Lamivudine group.(81.6% vs 51.3%;P0.005;44.9% vs 22.4%;P0.025;42.9% vs 20.4%;P0.025;79.6% vs 51.0%,P0.005).The efficacy of combination herapy appeared to be better than lamivudine group.Conclusion Marine combined with lamivudine and thymosin al in the treatment of chronic hepatitis B is better than single lamivudine.